This work aims to develop and elucidate the activation of Compound <b>2b</b>, a novel-structured small-molecule inhibitor of ADAM17, which was designed and developed and its therapeutic efficacy in NSCLC was assessed via multi-assays. The gene discussed is ADAM17; the disease is non-small cell lung carcinoma.